Getting a restful night’s sleep is often an elusive goal for many. Yet for someone living with type 1 diabetes (T1D), it can be more worrisome than challenging given the risk of hypoglycemia (low blood sugar). In fact, a new research study reveals that hypoglycemia can also induce abnormal heart rhythms, which in some cases could lead to cardiac failure.
Kaleb Dahlgren joins the #TeamT1D initiative by sharing his thoughts on misconceptions about T1D and the role the Canadian government can play in supporting those living with it.
Administering multiple insulin injections is one of the many daily burdens for people living with type 1 diabetes (T1D) – particularly among those with a needle phobia. However, a team of scientists is hoping to change all that with the development of an insulin pill to manage the condition.
A researcher from Milan, Italy has discovered that neutrophils – a type of white blood cell that forms an essential part of the immune system – can help identify triggers and predictors of progression to type 1 diabetes (T1D).
If you’re among those denied the Disability Tax Credit, you may need to reach out to the CRA.
For most people, a power failure is a huge inconvenience. However, for someone living with type 1 diabetes (T1D), it can be a daunting – and potentially fatal – experience since their insulin needs to be kept refrigerated.
How do you know which app might be helpful for you?
We sat down with our JDRF Marketing & Communications summer student, Evelyn Riddell, who lives with type 1 diabetes (T1D) to get her quick tips on how to drink responsibly with T1D.
The Environmental Determinants of Diabetes in the Young (TEDDY) is following more than 7,000 at-risk children from infancy to 15 years of age to determine the causes of T1D.
Evelyn, our Marketing Communications Assistant for the summer, was featured in the latest bra campaign, and the T1D community is loving it!
Imagine an automated insulin delivery system that is able to connect with other devices seamlessly. A state-of-the-art, tubeless technology that provides continuous insulin therapy, operates on its own platform and publishes its own communication protocol.
Researchers at Oxford University (UK) are offering powdered insulin to babies at high risk of developing type 1 diabetes (T1D) with the hope of training their immune systems to tolerate the insulin they produce, thereby offering life-long protection against the disease.
